Clinical guidelines for overactive bladder.
Yamaguchi
Osamu
O
Department of Urology, Fukushima Medical University, Fukushima-shi, Fukushima, Japan. yamaosa@fmu.ac.jp
Nishizawa
Osamu
O
Takeda
Masayuki
M
Yokoyama
Osamu
O
Homma
Yukio
Y
Kakizaki
Hidehiro
H
Obara
Kenji
K
Gotoh
Momokazu
M
Igawa
Yasuhiko
Y
Seki
Naarihito
N
Yoshida
Masaki
M
D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D032763:Behavior Control; D001905:Botulinum Toxins / Q000627:therapeutic use; D002211:Capsaicin / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D004224:Diterpenes / Q000627:therapeutic use; D005422:Flavoxate / Q000627:therapeutic use; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D018689:Sensory System Agents / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000175:diagnosis* / Q000628:therapy*
D018726:Anti-Dyskinesia Agents; D000928:Antidepressive Agents; D018680:Cholinergic Antagonists; D004224:Diterpenes; D010276:Parasympatholytics; D018689:Sensory System Agents; D005422:Flavoxate; C024353:resiniferatoxin; D001905:Botulinum Toxins; D002211:Capsaicin